Trial Profile
A Phase 1 Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Healthy Chinese Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2017
Price :
$35
*
At a glance
- Drugs Albinterferon alfa 2B (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Tianjin SinoBiotech
- 04 May 2017 Status changed from recruiting to completed.
- 03 Jun 2016 New trial record